Latest News for: constellation bones

Edit

Sara Sharif forced to wear hijab to school ‘to conceal injuries’

AOL 15 Oct 2024
Her body was discovered in a bed at her home in Woking, Surrey, on Aug 10 last year with an “awful constellation” of injuries including burns, bite marks, broken bones and extensive bruising ... But Sara was taken out of school in April 2023. .
Edit

Giles Coren on safari in Botswana: ‘Find me an aardvark!’

The Times/The Sunday Times 30 Aug 2024
But after we’d checked in with our hostess, Sandra, she and Bones and the cook and the waiter said they would be off ... And when we’d been going maybe an hour we stopped and Bones said, “You think you can walk in a straight line?”.
Edit

Guess this catchphrase sprawled all over an ancient temple

Metro UK 07 May 2024
According to Dr Worthington, each of the symbols can also be seen as a constellation ... However, there is no constellation based on a tree. In this case, Dr Worthington argues that the fig tree is a stand-in for the hard-to-draw Jaw constellation.
Edit

Mysterious symbols in ancient temple could be world’s oldest Catchphrase

Metro UK 06 May 2024
According to Dr Worthington, each of the symbols can also be seen as a constellation ... However, there is no constellation based on a tree. In this case, Dr Worthington argues that the fig tree is a stand-in for the hard-to-draw Jaw constellation.
Edit

MorphoSys AG Reports First Quarter 2024 Financial Results

Pharmiweb 29 Apr 2024
Additional secondary endpoints include progression-free survival, overall survival, duration of the splenic and total symptom score response, hemoglobin response rate and improvement in bone marrow fibrosis, among others.
Edit

MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation ...

ACCESSWIRE 24 Apr 2024
Additional secondary endpoints include progression-free survival, overall survival, duration of the splenic and total symptom score response, hemoglobin response rate and improvement in bone marrow fibrosis, among others.
Edit

MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting

Pharmiweb 24 Apr 2024
Additional secondary endpoints include progression-free survival, overall survival, duration of the splenic and total symptom score response, hemoglobin response rate and improvement in bone marrow fibrosis, among others.
Edit

MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Pharmiweb 13 Mar 2024
The combination therapy showed a strong positive trend in reducing symptom burden and improvements in measures of anemia and bone marrow fibrosis, and demonstrated safety results in line with assessments from prior clinical trials.
Edit

MorphoSys Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value

Pharmiweb 05 Feb 2024
Additional secondary endpoints include progression-free survival, overall survival, duration of the splenic and total symptom score response, hemoglobin response rate and improvement in bone marrow fibrosis, among others.
Edit

MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability

Pharmiweb 30 Jan 2024
Additional secondary endpoints include progression-free survival, overall survival, duration of the splenic and total symptom score response, hemoglobin response rate and improvement in bone marrow fibrosis, among others.
Edit

MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study 

Pharmiweb 11 Dec 2023
Improved bone marrow fibrosis by at least one grade in more patients versus placebo plus ruxolitinib ... an enlarged spleen, anemia, bone marrow fibrosis and disease-associated symptoms ... Improvement in Bone Marrow Fibrosis.
Edit

Ad hoc: MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction

Pharmiweb 20 Nov 2023
Additional secondary endpoints include progression-free survival, overall survival, duration of the splenic and total symptom score response, and improvement in bone marrow fibrosis, among others.
Edit

MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction

Pharmiweb 20 Nov 2023
Additional secondary endpoints include progression-free survival, overall survival, duration of the splenic and total symptom score response, and improvement in bone marrow fibrosis, among others.
Edit

MorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting

Pharmiweb 02 Nov 2023
... and total symptom score responses, and improvement in bone marrow fibrosis, among other endpoints. Constellation Pharmaceuticals, Inc., a MorphoSys company, is the MANIFEST-2 trial sponsor.
Edit

Sara Sharif's father and two other relatives to face trial next year over her death

ITV 19 Sep 2023
The father, stepmother and uncle of Sara Sharif will face trial next autumn as a court heard the 10-year-old suffered a “constellation” of injuries culminating in her death.

Most Viewed

×